Insulin-like growth factor 2 messenger RNA (IGF2 mRNA) (IGF2 mRNA)

Insulin-like growth factor 2 (IGF2) mRNA is the messenger RNA transcript that serves as the template for the synthesis of the IGF2 protein, a potent mitogen and key regulator of fetal growth and development [2, 14]. While its expression is tightly controlled by genomic imprinting in normal adult tissues, dysregulation—most notably the loss of imprinting—leads to the pathological overexpression of IGF2 mRNA in a wide range of human malignancies, including hepatocellular, colorectal, and pancreatic cancers [3, 6, 21]. This overexpression drives autocrine and paracrine signaling pathways that promote tumor cell proliferation, survival, and resistance to therapy [1, 19]. Consequently, IGF2 mRNA has emerged as a significant therapeutic target for RNA-centered modalities such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which aim to silence the gene before protein production occurs [6, 8, 17]. This strategy is particularly valuable for avoiding the cross-reactivity and metabolic toxicities often associated with targeting the IGF2 protein or the IGF1 receptor, which share high structural homology with the insulin receptor [6, 14]. Additionally, recent research has identified a role for IGF2 mRNA in the spinal cord during the development of neuropathic pain, suggesting broader therapeutic applications for its targeted inhibition [9, 18]. The stability and translation of IGF2 mRNA are further regulated by a family of RNA-binding proteins known as IGF2BPs, which are themselves emerging as critical oncogenic factors and therapeutic targets [1, 12, 23]. Therapeutic development focusing on IGF2 mRNA must address challenges such as efficient delivery to target tissues and the potential for off-target effects on normal growth and metabolic processes [9, 12].

Other names

IGF-II mRNA [11]Somatomedin-A mRNA [11]INSIGF mRNA [11]

Antisense inhibition or RNA interference (RNAi) leading to targeted degradation of the mRNA transcript or repression of translation, thereby reducing the production of the IGF2 protein [6, 8, 14, 17].